A pre-specified secondary analysis of the SELECT trial found that once-weekly semaglutide 2.4 mg modestly reduced a composite kidney endpoint versus placebo in adults with overweight or obesity and established cardiovascular disease, without diabetes. PICO summary and expert commentary.
Browsing: Semaglutide
Evidence summaries for semaglutide across type 2 diabetes, obesity, cardiovascular outcomes, kidney outcomes, safety, dosing, and comparative therapy.
Prespecified pooled analysis of the STEP-HFpEF program shows once-weekly semaglutide 2.4 mg improved NYHA functional class versus placebo in obesity-related HFpEF. PICO summary and expert commentary.
A prespecified secondary analysis of the STEP-HFpEF programme found that semaglutide 2.4 mg lowered NT-proBNP and produced larger health-status gains in patients with higher baseline NT-proBNP. PICO summary and expert commentary.
A post hoc analysis testing whether machine-learning digital pathology reproduces pathologist scoring of liver biopsies in a phase II semaglutide NASH trial. PICO summary and expert commentary.
A prespecified FLOW subgroup analysis tested whether semaglutide’s kidney and cardiovascular benefit held with or without baseline SGLT2 inhibitor use in type 2 diabetes and CKD. PICO summary and expert commentary.
Prespecified secondary analysis of the pooled STEP-HFpEF trials finds semaglutide 2.4 mg improves heart failure symptoms similarly in women and men, with greater weight loss in women. PICO summary and expert commentary.
A phase 1 trial characterising oral semaglutide pharmacokinetics, pharmacodynamics and tolerability in 32 healthy Chinese adults. PICO summary and expert commentary.
A prespecified analysis of the SELECT trial shows once-weekly semaglutide produced a placebo-subtracted weight reduction of 10.2% sustained to 208 weeks in adults with cardiovascular disease and overweight or obesity but without diabetes. PICO summary and expert commentary.
A pre-specified analysis of the SELECT trial assessing whether once-weekly semaglutide 2.4 mg improves kidney outcomes in adults with overweight or obesity and cardiovascular disease, without diabetes. PICO summary and expert commentary.
A prespecified pooled analysis of the STEP-HFpEF and STEP-HFpEF DM trials showing that once-weekly semaglutide 2.4 mg improved NYHA functional class versus placebo in obesity-related HFpEF. PICO summary and expert commentary.